BioMarin Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,312	942.84	755.13	724.53	587.28
Short-Term Investments	248.93	194.86	318.68	567.01	426.6
Cash & Short-Term Investments	1,561	1,138	1,074	1,292	1,014
Cash Growth	37.17%	5.95%	-16.86%	27.39%	-4.83%
Receivables	908.21	660.54	633.7	461.32	373.4
Inventory	1,299	1,233	1,107	894.08	776.67
Other Current Assets	185.78	201.53	141.39	104.52	110.44
Total Current Assets	3,953	3,232	2,956	2,751	2,274
Property, Plant & Equipment	991.8	1,077	1,112	1,114	1,082
Long-Term Investments	492.24	521.24	622.44	370.34	524.29
Goodwill	196.2	196.2	196.2	196.2	196.2
Other Intangible Assets	310.84	320.98	325.3	338.57	388.65
Long-Term Deferred Tax Assets	1,509	1,489	1,546	1,505	1,450
Other Long-Term Assets	140.76	151.94	83.56	98.78	89.2
Total Assets	7,594	6,989	6,842	6,375	6,005
Accounts Payable	312.77	235.4	315.51	231.24	199.68
Accrued Expenses	394.32	331.27	311.55	293.53	267.65
Current Portion of Long-Term Debt	-	-	493.88	-	-
Current Portion of Leases	8.69	7.57	8.78	10.38	10.46
Current Income Taxes Payable	3.67	12.57	2.65	16.21	1.21
Current Unearned Revenue	-	-	4.62	0.71	6.96
Other Current Liabilities	39.6	20.17	40.04	36.81	60.54
Total Current Liabilities	759.03	606.99	1,177	588.88	546.5
Long-Term Debt	597.18	595.14	593.1	1,083	1,079
Long-Term Leases	37.01	31.26	38.12	26.51	33.84
Other Long-Term Liabilities	113.8	97.57	81.81	73.5	79.69
Total Liabilities	1,507	1,331	1,890	1,772	1,739
Common Stock	0.19	0.19	0.19	0.19	0.18
Additional Paid-In Capital	5,957	5,802	5,612	5,405	5,192
Retained Earnings	154.21	-194.7	-621.55	-789.2	-930.76
Comprehensive Income & Other	-23.98	50.43	-38.65	-12.73	4.74
Shareholders' Equity	6,087	5,658	4,952	4,603	4,266
Total Liabilities & Equity	7,594	6,989	6,842	6,375	6,005
Total Debt	642.87	633.97	1,134	1,120	1,123
Net Cash (Debt)	917.74	503.74	-60.07	171.63	-109.51
Net Cash Growth	82.19%	-	-	-	-
Net Cash Per Share	4.65	2.56	-0.31	0.91	-0.60
Filing Date Shares Outstanding	192.32	190.78	188.68	186.53	184.03
Total Common Shares Outstanding	192.3	190.76	188.6	186.25	183.91
Working Capital	3,194	2,625	1,779	2,163	1,728
Book Value Per Share	31.65	29.66	26.25	24.71	23.19
Tangible Book Value	5,580	5,141	4,430	4,068	3,681
Tangible Book Value Per Share	29.02	26.95	23.49	21.84	20.01
Land	90.78	90.78	90.78	90.79	90.42
Buildings	910.71	892.48	860.81	819.1	774.92
Machinery	818.81	789.5	796.61	736.25	688.54
Construction In Progress	134.91	90.27	100.01	143.38	136.74
Leasehold Improvements	44.04	44.37	58.23	59.53	55.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.